Anti-Complement component C5b-9 (human)

CAT NO: DIA 011-01

Request Price

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Name*

First Last

Email*

Phone

Organization

Shipping Address*

City, State, Post Code/Zip*

Country*

States*

State

Catalog Number ( Product )

Message

Consent*

BioPorto is committed to protecting and respecting your privacy. Learn more about our data and privacy protection policy here. By submitting this form, you consent to allow BioPorto to store and process the personal information provided above to administer your account and provide the products and services you requested. You may unsubscribe from these communications at any time.

I agree

Product Name	Anti-Complement component C5b-9 (human)
Description	Mouse monoclonal antibody
Isotype	IgG2a/k
Host	Mouse
Clone	aE11
Conjugation	Unconjugated
Tested Applications	ELISA, WB, IHC, IF

ELISA	DIA 011-01 is well suited for quantifying TCC in ELISA. (2,3)
WB	DIA 011-01 is not recommended for Western blotting as the epitope is destroyed during the process. (4)
IHC	TCC in various tissues by immunohistochemistry (frozen and paraffin sections). (1, 2, 4)
	IHC staining of frozen tonsil section. Vascular endothelia and dendritic cells of germinal center have strong and intensive label. Dilution: 1:10
IF	DIA 011-01 can be used in immunofluorescence staining. (5)

Specificity
Specificity	DIA 011-01 binds both membrane-bound MAC (active) and fluid-phase SC5b-9 complexes (inactive). (1)DIA 011-01 binds to a neoepitope exposed on C9
Immunogen	Purified C5b-9
Target	C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8 and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual native components from which they are formed and DIA 011-01 is directed against a neoepitope exposed on C9 when incorporated into the TCC.
Gene ID	727
Species Reactivity POSITIVE	Human, Pig, Horse, Baboon
Species Reactivity NEGATIVE	Not determined

Properties
Form	Liquid
Unit Size	0,4 mL and 1 mL
Concentration	1 mg/mL ±15%, See CoA for lot details
Purification	Protein A or Protein G purified
Purification Notes	BSA free
Storage buffer	0.01 M phosphate buffer, pH 7.4, containing 0.15 M NaCl, 0,09% sodium azide

1. Mollnes TE, Harboe M (1987) Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology. Scand J Immunol 26:381-6.

2. Mollnes TE, Lea T, Harboe M, Tschopp J (1985) Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 22:183-195.

3. Palarasah,Y, Nielsen C, Sprogøe U, Christensen ML, Lillevang S, Madsen HO, Bygum A, Koch C, Skjodt K, Skjoed MO (2011) Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system. Clin Exp Immun 164: 388-395.

4. Mollnes TE (1997) Analysis of in vivo complement activation. Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C: Weir’s Handbook of Experimental Immunology. Boston, MA: Blackwell Science, pp. 78.1-78.8.

5. Jansen J, Høgåsen K, Mollnes T (1993) Extensive Complement Activation in Hereditary Porcine Membranoproliferative Glomerulonephritis Type 11 (Porcine Dense Deposit Disease. Am J Path 194: 1356-1365.

Downloads

Product Specifications

Related products

Anti-Complement component C5b-9 (human)

CAT NUMBER: DIA 011-01B

Anti-Complement component C5b-9 (human)

Request Price

AKI & NGAL

Products

About

Contact

Search

Anti-Complement component C5b-9 (human)

Request Price